December 8th, 2011

Blood-Test Case at Top U.S. Court May Send Patent ‘Shock Waves’

By

Computer, drug and biotechnology companies have a message for the U.S. Supreme Court as it prepares for arguments this week on patents for diagnostic medical tests: Be careful. Companies, trade groups and lawyers have filed more than two dozen legal briefs, many warning that the court’s ruling might have widespread, unintended ramifications. Each side in the case, which pits Nestle SA (NESN)’s Prometheus unit against the Mayo Clinic, says a defeat might stifle innovation.

Bloomberg, by Greg Stohr, 12/5/11

Tags: Legal / Leadership, Uncategorized

Contact Us · Privacy Policy